

World Journal of *Hepatology*

World J Hepatol 2022 March 27; 14(3): 482-646



REVIEW

- 482 Hepatitis E in immunocompromised individuals
Damiris K, Aghaie Meybodi M, Niazi M, Pyrsopoulos N

MINIREVIEWS

- 495 Small duct primary sclerosing cholangitis: A discrete variant or a bridge to large duct disease, a practical review
Nguyen CM, Kline KT, Stevenson HL, Khan K, Parupudi S
- 504 New progress in understanding roles of nitric oxide during hepatic ischemia-reperfusion injury
Zhang YP, Liu XR, Yang MW, Yang SL, Hong FF
- 516 Renal manifestations of hepatitis E among immunocompetent and solid organ transplant recipients
Kovvuru K, Carbajal N, Pakanati AR, Thongprayoon C, Hansrivijit P, Boonpheng B, Pattharanitima P, Nissaisorakarn V, Cheungpasitporn W, Kanduri SR
- 525 Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review
Spera AM

ORIGINAL ARTICLE**Basic Study**

- 535 Fertaric acid amends bisphenol A-induced toxicity, DNA breakdown, and histopathological changes in the liver, kidney, and testis
Korier KMM

Case Control Study

- 551 Prevalence of hypothyroidism and effect of thyroid hormone replacement therapy in patients with non-alcoholic fatty liver disease: A population-based study
Almomani A, Hitawala AA, Kumar P, Alqaisi S, Alshaikh D, Alkhayyat M, Asaad I

Retrospective Cohort Study

- 559 Standards of liver cirrhosis care in Central Australia
Raja SS, Batey RG, Edwards S, Aung HH
- 570 Risk factors and prediction of acute kidney injury after liver transplantation: Logistic regression and artificial neural network approaches
Bredt LC, Peres LAB, Risso M, Barros LCAL

Retrospective Study

- 583 Pediatric liver transplantation outcomes from a single center in Thailand

Prachuaphunyachart S, Sintusek P, Tubjareon C, Chaijitraruch N, Sanpavat A, Phewplung T, Wanawongsawad P, Intrarakamhang AL, Chongsrisawat V

Observational Study

- 592 Predictors of Mortality at 28-days in Infection associated Acute Kidney Injury in Cirrhosis

Gupta T, Ranga N, Goyal SK

- 602 Benign course of residual inflammation at end of treatment of liver transplant recipients after sofosbuvir based therapy

Ismail B, Benrajab KM, Bejarano P, Ruiz P, Sears D, Tzakis A, Zervos XB

- 612 Interrelationship between physical activity and depression in nonalcoholic fatty liver disease

Weinstein AA, De Avila L, Kannan S, Paik JM, Golabi P, Gerber LH, Younossi ZM

- 623 Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma

Mohamed GA, Nashaat EH, Fawzy HM, ElGhandour AM

Randomized Clinical Trial

- 634 Effect of a specific *Escherichia coli* Nissle 1917 strain on minimal/mild hepatic encephalopathy treatment

Manzhali E, Moyseyenko V, Kondratiuk V, Molochek N, Falalyeyeva T, Kobyliak N

ABOUT COVER

Editorial Board Member of *World Journal of Hepatology*, Rostyslav Bubnov, MD, PhD, LLB, Senior researcher in The Interferon Department of Zabolotny Institute of Microbiology and Virology, National Academy of Sciences of Ukraine; Medical doctor in The Center of Ultrasound Diagnostics and Interventional Sonography, Clinical Hospital "Pheophania" of Administration of President of Ukraine, Kyiv 03157, Ukraine. rostbubnov@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Hepatology (WJH, World J Hepatol)* is to provide scholars and readers from various fields of hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJH mainly publishes articles reporting research results and findings obtained in the field of hepatology and covering a wide range of topics including chronic cholestatic liver diseases, cirrhosis and its complications, clinical alcoholic liver disease, drug induced liver disease autoimmune, fatty liver disease, genetic and pediatric liver diseases, hepatocellular carcinoma, hepatic stellate cells and fibrosis, liver immunology, liver regeneration, hepatic surgery, liver transplantation, biliary tract pathophysiology, non-invasive markers of liver fibrosis, viral hepatitis.

INDEXING/ABSTRACTING

The *WJH* is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2021 edition of Journal Citation Reports® cites the 2020 Journal Citation Indicator (JCI) for *WJH* as 0.61. The *WJH*'s CiteScore for 2020 is 5.6 and Scopus CiteScore rank 2020: Hepatology is 24/62.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Rui-Rui Wu*; Production Department Director: *Xiang Li*; Editorial Office Director: *Xiang Li*.

NAME OF JOURNAL

World Journal of Hepatology

ISSN

ISSN 1948-5182 (online)

LAUNCH DATE

October 31, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Nikolaos Pylsopoulos, Ke-Qin Hu, Koo Jeong Kang

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1948-5182/editorialboard.htm>

PUBLICATION DATE

March 27, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Observational Study

Interrelationship between physical activity and depression in nonalcoholic fatty liver disease

Ali A Weinstein, Leyla De Avila, Saisruthi Kannan, James M Paik, Pegah Golabi, Lynn H Gerber, Zobair M Younossi

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): 0
Grade D (Fair): D, D
Grade E (Poor): 0

P-Reviewer: Christodoulou D, El-Gendy HA, Zhang LL

Received: October 19, 2021

Peer-review started: October 19, 2021

First decision: December 3, 2021

Revised: December 21, 2021

Accepted: February 20, 2022

Article in press: February 20, 2022

Published online: March 27, 2022



Ali A Weinstein, Leyla De Avila, James M Paik, Pegah Golabi, Lynn H Gerber, Zobair M Younossi, Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA 22042, United States

Ali A Weinstein, Saisruthi Kannan, Global and Community Health, George Mason University, Fairfax, VA 22030, United States

Lynn H Gerber, Zobair M Younossi, Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, VA 22042, United States

Zobair M Younossi, Inova Medicine, Inova Health System, Falls Church, VA 22042, United States

Corresponding author: Zobair M Younossi, AGAF, FACG, FACP, MD, Chairman, Professor, Inova Medicine, Inova Health System, Claude Moore Health Education and Research Building 3300 Gallows Road, Falls Church, VA 22042, United States. zobair.younossi@inova.org

Abstract

BACKGROUND

Nonalcoholic fatty liver disease (NAFLD) is associated with a sedentary lifestyle and depressive symptoms. It is also well established that physical inactivity and depressive symptoms are related. However, an investigation of the interaction between all of these factors in NAFLD has not been previously conducted.

AIM

To investigate the interrelationship between physical inactivity and depressive symptoms in individuals with NAFLD.

METHODS

Data from the Rancho Bernardo Study of Healthy Aging were utilized. 589 individuals were included in the analyses (43.1% male; 95.8% non-Hispanic white; aged 60.0 ± 7.0 years). NAFLD was defined by using the hepatic steatosis index, depression using the Beck Depression Inventory, and physical activity by self-report of number of times per week of strenuous activity. Multivariable generalized linear regression models with Gamma distribution were performed to investigate the proposed relationship.

RESULTS

About 40% of the sample had evidence of NAFLD, 9.3% had evidence of depression, and 29% were physically inactive. Individuals with NAFLD and depression were more likely to be physically inactive (60.7%) compared to individuals with neither NAFLD nor depression (22.9%), individuals with depression without NAFLD (37.0%), and individuals with NAFLD without depression (33.3%). After accounting for various comorbidities (*i.e.*, age, sex, diabetes, hypertension, obesity), individuals with NAFLD and higher levels of physical activity were at a decreased odds of having depressive symptoms [16.1% reduction (95% confidence interval: -25.6 to -5.4%), $P = 0.004$], which was not observed in those without NAFLD.

CONCLUSION

Individuals with NAFLD have high levels of physical inactivity, particularly those with depressive symptoms. Because this group is at high risk for poor outcomes, practitioners should screen for the coexistence of depressive symptoms and NAFLD. This group should receive appropriate interventions aimed at increasing both participation and levels of intensity of physical activity.

Key Words: Liver disease; Outcomes research; Psychiatric disorders; Exercise

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Physical inactivity and depressive symptoms are common in individuals with nonalcoholic fatty liver disease (NAFLD). Individuals with both NAFLD and depression are more likely to be sedentary than individuals without NAFLD or in individuals with NAFLD without depressive symptoms. Because this group is at high risk for poor outcomes, practitioners should screen for the coexistence of depressive symptoms and NAFLD. This group should receive appropriate interventions aimed at increasing both participation and levels of intensity of physical activity. It is therefore desirable that individuals with NAFLD should be screened for the presence of depressive symptoms to help determine appropriate interventions.

Citation: Weinstein AA, De Avila L, Kannan S, Paik JM, Golabi P, Gerber LH, Younossi ZM. Interrelationship between physical activity and depression in nonalcoholic fatty liver disease. *World J Hepatol* 2022; 14(3): 612-622

URL: <https://www.wjgnet.com/1948-5182/full/v14/i3/612.htm>

DOI: <https://dx.doi.org/10.4254/wjh.v14.i3.612>

INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver condition in the United States and globally[1]. NAFLD is a multisystem disease which can affect many organ systems and increase the risk of cardiovascular disease and type 2 diabetes mellitus, as well as numerous other conditions[2,3]. NAFLD, along with these other conditions, has been associated with a variety of behavioral factors, including a lack of physical activity, poor nutritional status, and substance consumption[4].

Specifically, a sedentary lifestyle has been related to the onset of NAFLD[5,6]. One potential pathway explaining this relationship is that a lack of physical activity is associated with obesity, which in turn is a major risk factor for NAFLD[5,7]. Increases in physical activity and exercise can lead to mobilization of fat from the liver and is suggested as a treatment for NAFLD[8-10]. Therefore, physical activity is an important behavior to understand in the context of NAFLD, both as a risk factor and as a treatment. Another factor that is highly related to physical inactivity is elevated depressive symptoms (both severity and frequency)[11]. In fact, there is a bi-directional relationship between a sedentary lifestyle and depressive symptoms such that physical inactivity is a risk factor for depressive symptoms and depressive symptoms are a risk factor for physical inactivity[5,12].

NAFLD has also been associated with depressive symptoms[13]. Individuals with NAFLD that also have a major depressive disorder are at an increased risk of developing other conditions such as cardiovascular diseases and stroke[14]. In general, individuals with elevated depressive symptoms have worse health outcomes, including increased morbidity and mortality [14]. Since one potential intervention for NAFLD is increasing levels of physical activity, it is important to consider the potential impact of depressive symptoms on the likelihood of participating in physical activity. It has been well established that individuals with depressive symptoms are less adherent to treatment for chronic illness, particularly treatments that involve behavioral changes[15].

Previous research has demonstrated the relationship between NAFLD and physical inactivity, between NAFLD and depressive symptoms, and between physical inactivity and depressive symptoms; however, we were not able to identify previous literature that explored the interaction of NAFLD, physical inactivity, and depressive symptoms together. The current investigation assesses the presence of these three factors in a community sample in order to explore the potential interrelationships.

MATERIALS AND METHODS

Data source and study population

The Rancho Bernardo Study (RBS) of Healthy Aging has been previously described in detail[16]. Briefly, between 1972 and 1974, 6339 (82%) adults from the predominantly white and middle to upper middle class southern California community of Rancho Bernardo were enrolled in a longitudinal study focusing on healthy aging. In addition, RBS focused on determining risk factors for cardiovascular disease, diabetes, cognitive function, and bone disease. Participants were followed *via* 12 subsequent clinic visits occurring approximately every four years as well as annual mailers to follow-up on health status and vital status through July 2019.

Our study utilized data from 1781 participants who completed clinic visit 7 (1992-1996). Clinic visit 7 was chosen because it assessed the factors necessary to establish presence or absence of NAFLD. Of these, we excluded 17 participants for missing the hepatic steatosis index (HSI), 55 participants for missing Beck Depression Inventory (BDI), and 221 participants who had a history of hepatitis, iron overload (iron \geq 198 mcg/dL in men and \geq 170 mcg/dL in women), or excessive alcohol consumption. As depression can manifest differently in older adults[17] and physical activity levels are different in older adults, we further excluded 899 participants aged 70 and over, leaving 589 participants in the final analytical sample (Figure 1). All participants provided written informed consent prior to participation at each visit.

Measurements

Demographic factors, lifestyle factors, laboratory measures, and medical history data were collected at clinic visit 7 (1992-1996). Lifestyle information was obtained through standard questionnaires and included smoking status [non-smoker, former smoker (quit \geq 2 years); active smoker], sedentary lifestyle (reported physical activity $<$ 3 times per week) and excessive alcohol consumption (\geq 2 drinks/day in men and \geq 1 drinks in women). Metabolic components were calculated by the following definitions: (1) Obesity pattern was categorized into lean (BMI: 18.5-25 kg/m²); overweight (25-29.9 kg/m²) and obese (\geq 30 kg/m²); (2) Hypertension was defined as having a systolic blood pressure of $>$ 140 mmHg or diastolic blood pressure of $>$ 90 mmHg from an average of three measurements and/or use of antihypertensive medications; (3) Hyperlipidemia was defined as a serum cholesterol level of \geq 200 mg/dL, LDL of \geq 130 mg/dL, and HDL \leq 40 mg/dL in men or \leq 50 mg/dL in women; (4) Diabetes mellitus was defined by a fasting glucose level \geq 126 mg/dL, post-challenge plasma glucose level of at least 200 mg/dL, and history of physician-diagnosed diabetes or use of diabetes medication; (5) Insulin resistance was defined by the homeostasis model assessment of insulin resistance[18]; and (6) Metabolic syndrome was defined as having at least three of the following: waist circumference $>$ 102 cm in men or $>$ 88 cm in women, fasting plasma glucose $>$ 110 mg/dL, blood pressure $>$ 130/85 mmHg, elevated triglycerides $>$ 150 mg/dL, and HDL \leq 40 mg/dL in men or \leq 50 mg/dL in women[19].

Definition of depression and physical activity

We categorized the presence of depression as a BDI score of \geq 10[20]. Individuals that scored less than 10 were considered to not have depression. We categorized physical activity into 3 groups: (1) "physical inactivity" if participants didn't engage in any level of physical activity at least three times per week; (2) "ideal physical activity" if participants regularly (\geq 3/week) engaged in strenuous activity; and (3) "moderate physical activity" that encompassed everyone else.

Definition of nonalcoholic fatty liver disease

NAFLD was defined by using the HSI, validated previously and used in epidemiologic studies[13,21,22] in the absence of secondary causes of liver disease. HSI was calculated by the following equation: $8 \times$ (alanine aminotransferase/aspartate aminotransferase ratio) + BMI (+2 for diabetes; +2 for female). The published cut-off score of 36 was utilized to define the presence of NAFLD. Participants with a HSI of $<$ 36 and no secondary causes of liver disease were presumed to not have the presence of NAFLD (non-NAFLD).

Statistical analysis

We compared demographic, lifestyle factors, clinical factors and medical history of the study cohort by the presence of NAFLD, depression and level of physical activity using a non-parametric Kruskal-Wallis test for continuous variables and chi-square test for categorical analysis. Multivariable generalized




Figure 1 Flow chart of study cohort selection. NAFLD: Nonalcoholic fatty liver disease.

linear regression model (GLM) with Gamma distribution was performed on BDI score to evaluate the effect of physical activity and NAFLD after adjusting for age, sex, current smoker, diabetes, hypertension, hyperlipidemia, obesity, history of cardiovascular disease and cancer. The adjusted relationship between factors and BDI scores was estimated using coefficients from GLM models, which were exponentiated to yield a percentage change in the outcome associated with each factor. Independent predictors of depression were studied using multivariable logistic regression. All differences reported here are statistically significant otherwise mentioned at the 0.05 Level. All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC).

RESULTS

Of 589 study subjects (43.1% male; 95.8% non-Hispanic white; mean (SD) age 60.0 (7.0) years), 235 (39.9%) subjects had evidence of NAFLD and 55 (9.3%) had evidence of depression. Furthermore, 12.6% had diabetes, 75.7% had hyperlipidemia, 20.0% had hypertension, 26.7% had insulin resistance, 29.0% were physically inactive and 11.9% were active smokers.

Compared to individuals without NAFLD, individuals with NAFLD were statistically significantly more commonly male (52.3% *vs* 37.0%), more likely to be overweight/obese (93.6% *vs* 28.0%) more likely to have insulin resistance (46.4% *vs* 13.6%), hyperlipidemia (85.5% *vs* 69.2%), diabetes (23.4% *vs* 5.4%), and metabolic syndrome (43.4% *vs* 6.5%) (all $P < 0.02$). Among individuals with NAFLD, 36.6% fell into the physical inactivity category and 24.7% were in the ideal physical activity category; whereas among individuals without NAFLD, 24.0% fell into the physical inactivity category and 36.7% were in the ideal physical activity category ($P < 0.002$) (Table 1). Individuals with NAFLD had a statistically significantly higher mean BDI score than those without NAFLD (4.49 *vs* 3.67, $P = 0.004$), although the mean scores were relatively low in each group.

Of the entire cohort, 4.8% had both NAFLD and depression, 4.6% had depression without NAFLD, 35.1% had NAFLD without depression and 55.5% had neither depression nor NAFLD. Demographic, lifestyle and general health comorbidities of participants according to the presence of NAFLD and depression status are presented in Table 2. Compared to individuals with NAFLD but no depression, individuals with both NAFLD and depression were more likely to have a history of arthritis (17.6% *vs* 10.5%). Compared to individuals with depression but no NAFLD, individuals with both NAFLD and depression were less likely to be lean (7.1% *vs* 85.2%) and have a higher rate of insulin resistance (42.9% *vs* 3.7%) and metabolic syndrome (39.3% *vs* 7.4%).

Table 1 Demographic, lifestyle and general health comorbidities of participants according to the presence of nonalcoholic fatty liver disease

	All (n = 589)	Non-NAFLD (n = 354)	NAFLD (n = 235)	P value
Age, mean ± SD	59.97 ± 6.97	59.99 ± 7.40	59.94 ± 6.29	0.3959
Male, %	254 (43.12%)	131 (37.01%)	123 (52.34%)	0.0002
White, %	564 (95.76%)	340 (96.05%)	224 (95.32%)	0.6686
Smoking status, %				
Current	70 (11.90%)	47 (13.31%)	23 (9.79%)	0.1958
Former	239 (40.65%)	141 (39.94%)	98 (41.70%)	0.6706
Non-smoker	279 (47.45%)	165 (46.74%)	114 (48.51%)	0.674
Regular exercise, %				
Physically Inactive	171 (29.03%)	85 (24.01%)	86 (36.60%)	0.001
Moderate physical activity	230 (39.05%)	139 (39.27%)	91 (38.72%)	0.8949
Ideal physical activity	188 (31.92%)	130 (36.72%)	58 (24.68%)	0.0021
Obesity, % BMI				
Lean	270 (45.84%)	255 (72.03%)	15 (6.38%)	< 0.0001
Overweight	234 (39.73%)	99 (27.97%)	135 (57.45%)	< 0.0001
Obese	85 (14.43%)	0 (0.00%)	85 (36.17%)	< 0.0001
History of CVD, %	40 (6.79%)	23 (6.50%)	17 (7.23%)	0.7278
History of arthritis, %	68 (11.54%)	39 (11.02%)	29 (12.34%)	0.6226
History of cancer (any), %	97 (16.47%)	48 (13.56%)	49 (20.85%)	0.0195
Insulin resistance, %	157 (26.66%)	48 (13.56%)	109 (46.38%)	< 0.0001
Hypertension, %	117 (19.86%)	66 (18.64%)	51 (21.70%)	0.3623
Hyperlipidemia, %	446 (75.72%)	245 (69.21%)	201 (85.53%)	< 0.0001
Diabetes, %	74 (12.56%)	19 (5.37%)	55 (23.40%)	< 0.0001
Metabolic syndrome ¹ , %	125 (21.26%)	23 (6.52%)	102 (43.40%)	< 0.0001
BDI, mean ± SD	4.00 ± 3.71	3.67 ± 3.62	4.49 ± 3.80	0.0041

CVD: Cardiovascular disease; NAFLD: Nonalcoholic fatty liver disease; SD: Standard deviation. NCEP ATP III (2005 revision).

¹P value by nonparametric Kruskal-Wallis Test for continuous variables, chi-square test for categorical variable, Data are presented as the mean ± SD for numerical variables and count (%) for categorical variables.

For the individuals that had NAFLD and depression, 60.7% fell within the physical inactivity category which is statistically significantly greater than all of the other groups [individuals with neither NAFLD nor depression (22.9%), individuals with depression without NAFLD (37.0%), and individuals with NAFLD without depression (33.3%)] (Figure 2). Characteristics of individuals according to the presence of NAFLD and physical activity are presented in Supplementary Table 1.

In stratified analyses across the presence of NAFLD, accounting for age, sex, current smoker, diabetes, hypertension, hyperlipidemia, obesity, history of cardiovascular disease and any cancer in GLMs, individuals with NAFLD and higher levels of physical activity experienced greater odds of having a lower BDI score [16.1% reduction (95% confidence interval: -25.6 to -5.4%), $P = 0.004$]. This association between level of activity and BDI scores was not observed in those without NAFLD (Table 3).

To assess the association of physical activity and NAFLD on BDI scores, GLMs were performed (Table 4). In the unadjusted model, compared with non-NAFLD individuals with an ideal level of physical activity, NAFLD individuals with physical inactivity had an increased BDI score [46.8% increase (19.3 to 80.8%), $P < 0.001$]. Even in the fully adjusted model, this result was consistently observed [36.3% increase (9.1 to 70.2%) $P < 0.001$]. Non-NAFLD Individuals with physical inactivity did not statistically significantly differ from non-NAFLD individuals with an ideal level of physical activity ($P = 0.465$).

Table 2 Demographic, lifestyle and general health comorbidities of participants according to the presence of depression and nonalcoholic fatty liver disease

	Individuals with NAFLD			Individuals without NAFLD		
	No depression (n = 207)	Depression (n = 28)	P value	No depression (n = 327)	Depression (n = 27)	P value
Age, mean ± SD	59.91 ± 6.34	60.15 ± 6.00	0.9433	60.02 ± 7.32	59.61 ± 8.44	0.9813
Male, %	115 (55.56%)	8 (28.57%)	0.0073	125 (38.23%)	6 (22.22%)	0.0978
White, %	197 (95.17%)	27 (96.43%)	0.7671	316 (96.64%)	24 (88.89%)	0.0471
Smoking status, %						
Current	19 (9.18%)	4 (14.29%)	0.3934	41 (12.58%)	6 (22.22%)	0.1563
Former	86 (41.55%)	12 (42.86%)	0.8949	133 (40.80%)	8 (29.63%)	0.2549
Non-smoker	102 (49.28%)	12 (42.86%)	0.5236	152 (46.63%)	13 (48.15%)	0.8789
Regular exercise, %						
Physically inactive	69 (33.33%)	17 (60.71%)	0.0048	75 (22.94%)	10 (37.04%)	0.0992
Moderate physical activity	86 (41.55%)	5 (17.86%)	0.0157	129 (39.45%)	10 (37.04%)	0.8051
Ideal physical activity	52 (25.12%)	6 (21.43%)	0.6706	123 (37.61%)	7 (25.93%)	0.2259
Obesity, % BMI						
Lean	13 (6.28%)	2 (7.14%)	0.8609	232 (70.95%)	23 (85.19%)	0.1132
Overweight	118 (57.00%)	17 (60.71%)	0.7094	95 (29.05%)	4 (14.81%)	0.1132
Obese	76 (36.71%)	9 (32.14%)	0.6365	0 (0.00%)	0 (0.00%)	-----
History of CVD, %	14 (6.76%)	3 (10.71%)	0.4488	21 (6.42%)	2 (7.41%)	0.8417
History of arthritis, %	21 (10.14%)	8 (28.57%)	0.0054	37 (11.31%)	2 (7.41%)	0.5331
History of any cancer, %	46 (22.22%)	3 (10.71%)	0.1595	47 (14.37%)	1 (3.70%)	0.1196
Insulin resistance, %	97 (46.86%)	12 (42.86%)	0.6902	47 (14.37%)	1 (3.70%)	0.1196
Hypertension, %	44 (21.26%)	7 (25.00%)	0.6519	61 (18.65%)	5 (18.52%)	0.9861
Hyperlipidemia, %	177 (85.51%)	24 (85.71%)	0.9767	226 (69.11%)	19 (70.37%)	0.8918
Diabetes, %	50 (24.15%)	5 (17.86%)	0.4601	16 (4.89%)	3 (11.11%)	0.1682
Metabolic syndrome ¹ , %	91 (43.96%)	11 (39.29%)	0.6394	21 (6.44%)	2 (7.41%)	0.8451

CVD: Cardiovascular disease; SD: Standard deviation; NAFLD: Nonalcoholic fatty liver disease, NCEP ATP III (2005 revision).

¹P value by nonparametric Kruskal-Wallis Test for continuous variables, chi-square test for categorical variable. Data are presented as the mean ± SD for numerical variables and count (%) for categorical variables.

In multivariable logistic regression, we included in the model: NAFLD, diabetes, age, sex, smoking status, hypertension, hyperlipidemia, cardiovascular disease, and cancer. The statistically significant risk factors of depression were NAFLD Odds Ratio (OR 2.01 1.08-3.72), $P = 0.028$, being male [OR 0.37 (0.19-0.72), $P = 0.003$] and physical inactivity [OR 1.68 (0.78-3.65), $P = 0.005$] ([Supplementary Table 2](#)).

DISCUSSION

This study investigated the interrelationships between NAFLD, depressive symptoms and physical activity. Our results demonstrate a strong likelihood of physical inactivity in individuals with NAFLD and depression, which was at a higher rate than was seen in individuals without NAFLD or in individuals with NAFLD without depressive symptoms.

Similar findings have been found in individuals with type 2 diabetes[23]. Various symptoms of depression (lack of motivation, low self-esteem, feelings of helplessness, anhedonia) might explain why individuals with depressive symptoms are more often physically inactive[24], but having only depression in this cohort did not explain the inactivity level. The co-existence between NAFLD and depression is likely to associate with physical inactivity.

Table 3 Univariable and multivariable changes in beck depression inventory according to physical activity, stratified by the presence of nonalcoholic fatty liver disease

	NAFLD		Non-NAFLD	
	% change (95%CI)	P	% change (95%CI)	P
Unadjusted	-16.91 (-26.28 - -6.35)	0.0024	-8.96 (-18.25 - 1.38)	0.0871
Age-sex adjusted	-14.74 (-24.42 - -3.83)	0.0095	-6.79 (-16.35 - 3.87)	0.203
Model 1	-14.6 (-24.34 - -3.61)	0.01	-3.43 (-13.64 - 7.98)	0.54
Model 2	-16.12 (-25.6 - -5.44)	0.004	-3.27 (-13.49 - 8.15)	0.5592

Generalized linear regression with a gamma error distribution and a log-link function. Level of Physical activity is defined as a continuous variable (1 = inactive, 2 = moderate, 3 = Ideal); Model 1 adjusted for Physical activity, age, sex, current smoker, DM, hypertension, hyperlipidemia and obesity; Model 2 adjusted for all variables in model 1 + history of CVD and history of cancer. NAFLD: Nonalcoholic fatty liver disease.

Table 4 Univariable and multivariable changes in beck depression inventory score according to the presence of nonalcoholic fatty liver disease and level of physical activity

Group	Unadjusted		Age-sex adjusted		Model 1		Model 2	
	% change (95%CI)	P	% change (95%CI)	P	% change (95%CI)	P	% change (95%CI)	P
Non-NAFLD with physical ideal	Reference		Reference		Reference		Reference	
Non-NAFLD with physical moderate	16.67 (-3.33 - 40.82)	0.108	11.5 (-7.68 - 34.67)	0.2584	7.77 (-11.05 - 30.58)	0.4447	6.99 (-11.65 - 29.56)	0.4891
Non-NAFLD with physical inactivity	19.85 (-2.87 - 47.89)	0.0913	14.15 (-7.5 - 40.87)	0.2174	8.25 (-12.74 - 34.29)	0.4708	8.34 (-12.58 - 34.26)	0.4645
NAFLD with physical ideal	1.23 (-20.04 - 28.15)	0.919	3.31 (-18.23 - 30.53)	0.7849	-2.43 (-24.49 - 26.08)	0.851	-2.19 (-24.33 - 26.45)	0.866
NAFLD with physical moderate	23.08 (-0.09 - 51.63)	0.051	23.99 (0.79 - 52.53)	0.042	15.68 (-7.7 - 44.98)	0.206	16.24 (-7.23 - 45.65)	0.1911
NAFLD with physical inactivity	46.84 (19.28 - 80.75)	0.0003	43.06 (16.39 - 75.84)	0.0007	35.02 (8.03 - 68.74)	0.0083	36.25 (9.1 - 70.16)	0.0064

Generalized linear regression with a gamma error distribution and a log-link function. Level of Physical activity is defined as a continuous variable (1 = Poor, 2 = moderate, 3 = Ideal); Model 1 adjusted for Physical activity, age, sex, current smoker, DM, hypertension, hyperlipidemia and obesity; Model 2 adjusted for all variables in model 1 + history of CVD and history of cancer. NAFLD: Nonalcoholic fatty liver disease.

Depression and NAFLD occur together more often than would be predicted by chance[25]. There are many potential factors that may help to explain this overlap, including the presence of diabetes and obesity, both risk factors for NAFLD and depression[25]. Another area of overlap is the increase in circulating inflammatory cytokines in both depression and NAFLD[26]. In addition, physical inactivity is a risk factor for both depression and NAFLD[5,11]. However, further investigation is needed to clarify this bi-directional relationship between depression and NAFLD.

The findings of the current study show that both physical inactivity and depressive symptoms are common in individuals with NAFLD. In addition, individuals with NAFLD and depressive symptoms are much more likely to be physically inactive than people with depression without NAFLD and those without either. NAFLD is a risk factor for all-cause mortality and exercise is an antidote to this. The combination of depression and NAFLD is significantly associated with low level of physical activity, which in itself is a risk for all-cause mortality. It is therefore desirable that individuals with NAFLD should be screened for the presence of depressive symptoms. Depressive symptoms are likely to contribute to a low level of physical activity, and if treated, may increase participation in more vigorous activity for greater durations. Additionally, increased physical activity has been shown to help mobilize fat from the liver[8,9], and increased physical activity has been shown to have anti-depressive effects [27]. Therefore, it may be important to screen for the combined presence of NAFLD and depression, treat each appropriately, and aim to maximize participation in physical activity. Longitudinal studies




Figure 2 Percentage distribution of physical activity, by the presence of nonalcoholic fatty liver disease and depressive symptoms.
NAFLD: Nonalcoholic fatty liver disease.

investigating these interrelationships are needed to determine if physical inactivity is one of the factors that may link depressive symptoms to subsequent poor health outcomes in NAFLD patients.

Some limitations should be noted. Due to the cross-sectional nature of the current investigation, no causal relationships nor directionality can be inferred between physical inactivity, depressive symptoms, and NAFLD. Another limitation is that we used a noninvasive test (HSI) to identify NAFLD rather than a liver biopsy or other sensitive radiologic tests since these were not available. An objective method of physical activity assessment (*i.e.*, an activity monitor) was not available. In addition, these data were collected in 1992-1996, therefore an older version of the BDI was used and the diagnosis of viral hepatitis was relatively new at the time. We also acknowledge that our findings are not generalizable to the general population, as all participants were well educated, medically insured, predominantly white, and middle to upper-middle-class. Lastly, participants have a relatively low prevalence of obesity, diabetes, and metabolic syndrome compared to the National Health and Nutrition Examination Survey III[28] which may have influenced the results.

CONCLUSION

Individuals with NAFLD have high levels of physical inactivity, particularly those with depressive symptoms. Because this group is at high risk for poor outcomes, practitioners should screen for the coexistence of depressive symptoms and NAFLD. This group should receive appropriate interventions aimed at increasing both participation and levels of intensity of physical activity.

ARTICLE HIGHLIGHTS

Research background

Since one potential intervention for nonalcoholic fatty liver disease (NAFLD) is increasing levels of physical activity, it is important to consider the potential impact of depressive symptoms on the likelihood of participating in physical activity. It has been well established that individuals with depressive symptoms are less adherent to treatment for chronic illness, particularly treatments that involve behavioral changes.

Research motivation

Previous research has demonstrated the relationship between NAFLD and physical inactivity, between NAFLD and depressive symptoms, and between physical inactivity and depressive symptoms; however, we were not able to identify previous literature that explored the interaction of NAFLD, physical inactivity, and depressive symptoms together.

Research objectives

The current investigation assesses the presence of NAFLD, physical inactivity, and depressive symptoms in a community sample in order to explore the potential interrelationships.

Research methods

Data from the Rancho Bernardo Study were used. 589 individuals were included in the analyses (43.1% male; 95.8% non-Hispanic white; aged 60.0 ± 7.0 years). NAFLD was defined by using the hepatic steatosis index, depression using the Beck Depression Inventory, and physical activity by self-report of number of times per week of strenuous activity. Multivariable generalized linear regression models with Gamma distribution were performed to investigate the proposed relationship.

Research results

About 40% of the sample had evidence of NAFLD, 9.3% had evidence of depression, and 29% were physically inactive. Individuals with NAFLD and depression were more likely to be physically inactive (60.7%) compared to individuals with neither NAFLD nor depression (22.9%), individuals with depression without NAFLD (37.0%), and individuals with NAFLD without depression (33.3%). After accounting for various comorbidities (*i.e.*, age, sex, diabetes, hypertension, obesity), individuals with NAFLD and higher levels of physical activity were at a decreased odds of having depressive symptoms [16.1% reduction (95% confidence interval: -25.6 to -5.4%), $P = 0.004$], which was not observed in those without NAFLD.

Research conclusions

Individuals with NAFLD have high levels of physical inactivity, particularly those with depressive symptoms. Because this group is at high risk for poor outcomes, practitioners should screen for the coexistence of depressive symptoms and NAFLD. This group should receive appropriate interventions aimed at increasing both participation and levels of intensity of physical activity.

Research perspectives

Further investigation is needed to clarify this bi-directional relationship between depression and NAFLD. Future work should explore screening for the combined presence of NAFLD and depression to determine if treatment with appropriate physical activity interventions can enhance outcomes.

FOOTNOTES

Author contributions: Weinstein AA, de Avila, L, Golabi P, Gerber LH, and Younossi ZM designed the research study; Paik JM analyzed the data; and Weinstein AA, Kannan S, de Avila L, and Paik JM wrote the manuscript; all authors have read and approve the final manuscript.

Supported by Betty and Guy Beatty Center for Integrated Research.

Institutional review board statement: This study is the analysis of de-identified, publicly available data and does not constitute human subjects research, therefore it does not need institutional review board approval.

Informed consent statement: This is a secondary data analysis of a publicly available deidentified data, therefore, informed ethics committee approval and informed consent is not relevant here. The original data collection adhered to all ethical standards (ethics committee approval and informed consent).

Conflict-of-interest statement: Dr. Zobair M Younossi is a consultant to BMS, Gilead, AbbVie, Intercept, and GSK. All other authors report no proprietary or commercial interest in any product or concept discussed in this article.

Data sharing statement: Data are available by request from <https://knit.ucsd.edu/ranchobernardostudy/access/>

STROBE statement: The authors have read the STROBE Statement – checklist of items, and the manuscript was prepared and revised according to the STROBE Statement – checklist of items.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license

their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: United States

ORCID number: Ali A Weinstein 0000-0002-3371-6086; Leyla De Avila 0000-0003-3731-8058; Saisruthi Kannan 0000-0001-8557-5054; James M Paik 0000-0003-2294-323X; Pegah Golabi 0000-0001-9818-0983; Lynn H Gerber 0000-0001-7525-680X; Zobair M Younossi 0000-0001-9313-577X.

S-Editor: Ma YJ

L-Editor: A

P-Editor: Ma YJ

REFERENCES

- 1 **Argo CK**, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. *Clin Liver Dis* 2009; **13**: 511-531 [PMID: 19818302 DOI: 10.1016/j.cld.2009.07.005]
- 2 **Li AA**, Ahmed A, Kim D. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. *Gut Liver* 2020; **14**: 168-178 [PMID: 31195434 DOI: 10.5009/gnl19069]
- 3 **Byrne CD**, Targher G. NAFLD: a multisystem disease. *J Hepatol* 2015; **62**: S47-S64 [PMID: 25920090 DOI: 10.1016/j.jhep.2014.12.012]
- 4 **Macavei B**, Baban A, Dumitrascu DL. Psychological factors associated with NAFLD/NASH: a systematic review. *Eur Rev Med Pharmacol Sci* 2016; **20**: 5081-5097 [PMID: 28051263]
- 5 **Croci I**, Coombes JS, Bucher Sandbakk S, Keating SE, Nauman J, Macdonald GA, Wisloff U. Non-alcoholic fatty liver disease: Prevalence and all-cause mortality according to sedentary behaviour and cardiorespiratory fitness. The HUNT Study. *Prog Cardiovasc Dis* 2019; **62**: 127-134 [PMID: 30796942 DOI: 10.1016/j.pcad.2019.01.005]
- 6 **Kwak MS**, Kim D. Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity. *Korean J Intern Med* 2018; **33**: 64-74 [PMID: 29202557 DOI: 10.3904/kjim.2017.343]
- 7 Correction: Dose-response association between physical activity and non-alcoholic fatty liver disease: a case-control study in a Chinese population. *BMJ Open* 2020; **10**: e026854corr1 [PMID: 32029501 DOI: 10.1136/bmjopen-2018-026854corr1]
- 8 **Gerber LH**, Weinstein A, Pawloski L. Role of exercise in optimizing the functional status of patients with nonalcoholic fatty liver disease. *Clin Liver Dis* 2014; **18**: 113-127 [PMID: 24274868 DOI: 10.1016/j.cld.2013.09.016]
- 9 **Abdelbasset WK**, Tantawy SA, Kamel DM, Alqahtani BA, Elnegamy TE, Soliman GS, Ibrahim AA. Effects of high-intensity interval and moderate-intensity continuous aerobic exercise on diabetic obese patients with nonalcoholic fatty liver disease: A comparative randomized controlled trial. *Medicine (Baltimore)* 2020; **99**: e19471 [PMID: 32150108 DOI: 10.1097/MD.00000000000019471]
- 10 **Locklear CT**, Golabi P, Gerber L, Younossi ZM. Exercise as an intervention for patients with end-stage liver disease: Systematic review. *Medicine (Baltimore)* 2018; **97**: e12774 [PMID: 30334965 DOI: 10.1097/MD.00000000000012774]
- 11 **Achtstien R**, van Lieshout J, Wensing M, van der Sanden MN, Staal JB. Symptoms of depression are associated with physical inactivity but not modified by gender or the presence of a cardiovascular disease; a cross-sectional study. *BMC Cardiovasc Disord* 2019; **19**: 95 [DOI: 10.1186/s12872-019-1065-8]
- 12 **Jung JY**, Park SK, Oh CM, Chung PW, Ryou JH. Non-Alcoholic Fatty Liver Disease and Its Association with Depression in Korean General Population. *J Korean Med Sci* 2019; **34**: e199 [PMID: 31373184 DOI: 10.3346/jkms.2019.34.e199]
- 13 **Kim D**, Yoo ER, Li AA, Tighe SP, Cholankeril G, Harrison SA, Ahmed A. Depression is associated with non-alcoholic fatty liver disease among adults in the United States. *Aliment Pharmacol Ther* 2019; **50**: 590-598 [PMID: 31328300 DOI: 10.1111/apt.15395]
- 14 **Tomeno W**, Kawashima K, Yoneda M, Saito S, Ogawa Y, Honda Y, Kessoku T, Imajo K, Mawatari H, Fujita K, Hirayasu Y, Nakajima A. Non-alcoholic fatty liver disease comorbid with major depressive disorder: The pathological features and poor therapeutic efficacy. *J Gastroenterol Hepatol* 2015; **30**: 1009-1014 [PMID: 25619308 DOI: 10.1111/jgh.12897]
- 15 **Lam WY**, Fresco P. Medication Adherence Measures: An Overview. *Biomed Res Int* 2015; **2015**: 217047 [PMID: 26539470 DOI: 10.1155/2015/217047]
- 16 **Barrett-Connor E**. The prevalence of diabetes mellitus in an adult community as determined by history or fasting hyperglycemia. *Am J Epidemiol* 1980; **111**: 705-712 [PMID: 7386445 DOI: 10.1093/oxfordjournals.aje.a112948]
- 17 **Haigh EAP**, Bogucki OE, Sigmon ST, Blazer DG. Depression Among Older Adults: A 20-Year Update on Five Common Myths and Misconceptions. *Am J Geriatr Psychiatry* 2018; **26**: 107-122 [PMID: 28735658 DOI: 10.1016/j.jagp.2017.06.011]
- 18 **Matthews DR**, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985; **28**: 412-419 [PMID: 3899825 DOI: 10.1007/BF00280883]
- 19 **Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report.** *Circulation*. 2002; 106. Available from: <https://pubmed.ncbi.nlm.nih.gov/12485966/>
- 20 **Beck AT**, Steer RA, Carbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. *Clin Psychol Rev* 1988; **8**: 77-100 [DOI: 10.1016/0272-7358(88)90050-5]
- 21 **Lee JH**, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, Kim YJ, Yoon JH, Cho SH, Sung MW, Lee HS. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. *Dig Liver Dis* 2010; **42**: 503-508 [PMID: 20311111 DOI: 10.1016/j.dld.2010.05.005]

- 19766548 DOI: [10.1016/j.dld.2009.08.002](https://doi.org/10.1016/j.dld.2009.08.002)]
- 22 **Meffert PJ**, Baumeister SE, Lerch MM, Mayerle J, Kratzer W, Völzke H. Development, external validation, and comparative assessment of a new diagnostic score for hepatic steatosis. *Am J Gastroenterol* 2014; **109**: 1404-1414 [PMID: [24957156](https://pubmed.ncbi.nlm.nih.gov/24957156/) DOI: [10.1038/ajg.2014.155](https://doi.org/10.1038/ajg.2014.155)]
 - 23 **Koopmans B**, Pouwer F, de Bie RA, van Rooij ES, Leusink GL, Pop VJ. Depressive symptoms are associated with physical inactivity in patients with type 2 diabetes. The DIAZOB Primary Care Diabetes study. *Fam Pract* 2009; **26**: 171-173 [PMID: [19321598](https://pubmed.ncbi.nlm.nih.gov/19321598/) DOI: [10.1093/fampra/cmp016](https://doi.org/10.1093/fampra/cmp016)]
 - 24 **Seime RJ**, Vickers KS. The challenges of treating depression with exercise: From evidence to practice. *Clin Psychol Sci Pract* 2006; **13**: 194-197 [DOI: [10.1111/j.1468-2850.2006.00022.x](https://doi.org/10.1111/j.1468-2850.2006.00022.x)]
 - 25 **Xiao J**, Lim LKE, Ng CH, Tan DJH, Lim WH, Ho CSH, Tan EXX, Sanyal AJ, Muthiah MD. Is Fatty Liver Associated With Depression? *Front Med (Lausanne)* 2021; **8**: 691696 [PMID: [34277666](https://pubmed.ncbi.nlm.nih.gov/34277666/) DOI: [10.3389/fmed.2021.691696](https://doi.org/10.3389/fmed.2021.691696)]
 - 26 **Lee JW**, Park SH. Association between depression and nonalcoholic fatty liver disease: Contributions of insulin resistance and inflammation. *J Affect Disord* 2021; **278**: 259-263 [PMID: [32977263](https://pubmed.ncbi.nlm.nih.gov/32977263/) DOI: [10.1016/j.jad.2020.09.073](https://doi.org/10.1016/j.jad.2020.09.073)]
 - 27 **Motl RW**, Konopack JF, McAuley E, Elavsky S, Jerome GJ, Marquez DX. Depressive symptoms among older adults: long-term reduction after a physical activity intervention. *J Behav Med* 2005; **28**: 385-394 [PMID: [16049630](https://pubmed.ncbi.nlm.nih.gov/16049630/) DOI: [10.1007/s10865-005-9005-5](https://doi.org/10.1007/s10865-005-9005-5)]
 - 28 **Paik JM**, Deshpande R, Golabi P, Younossi I, Henry L, Younossi ZM. The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease. *Aliment Pharmacol Ther* 2020; **51**: 291-304 [PMID: [31782543](https://pubmed.ncbi.nlm.nih.gov/31782543/) DOI: [10.1111/apt.15580](https://doi.org/10.1111/apt.15580)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: bpgoffice@wjgnet.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

